Mesoblast Statistics
Total Valuation
Mesoblast has a market cap or net worth of $2.05 billion. The enterprise value is $2.06 billion.
Important Dates
The last earnings date was Thursday, February 26, 2026, after market close.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mesoblast has 1.29 billion shares outstanding. The number of shares has increased by 14.57% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.29B |
| Shares Change (YoY) | +14.57% |
| Shares Change (QoQ) | +11.47% |
| Owned by Insiders (%) | 32.66% |
| Owned by Institutions (%) | 26.89% |
| Float | 859.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 31.40 |
| Forward PS | 19.80 |
| PB Ratio | 3.57 |
| P/TBV Ratio | 348.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 31.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.24.
| Current Ratio | 1.58 |
| Quick Ratio | 1.35 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.67 |
Financial Efficiency
Return on equity (ROE) is -18.22% and return on invested capital (ROIC) is -6.70%.
| Return on Equity (ROE) | -18.22% |
| Return on Assets (ROA) | -6.06% |
| Return on Invested Capital (ROIC) | -6.70% |
| Return on Capital Employed (ROCE) | -10.63% |
| Weighted Average Cost of Capital (WACC) | 8.84% |
| Revenue Per Employee | $807,210 |
| Profits Per Employee | -$1.17M |
| Employee Count | 81 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 2.07 |
Taxes
In the past 12 months, Mesoblast has paid $563,000 in taxes.
| Income Tax | 563,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +0.95% in the last 52 weeks. The beta is 0.76, so Mesoblast's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | +0.95% |
| 50-Day Moving Average | 17.93 |
| 200-Day Moving Average | 15.49 |
| Relative Strength Index (RSI) | 38.76 |
| Average Volume (20 Days) | 193,138 |
Short Selling Information
| Short Interest | 2.68M |
| Short Previous Month | 2.64M |
| Short % of Shares Out | 2.56% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 10.06 |
Income Statement
In the last 12 months, Mesoblast had revenue of $65.38 million and -$94.37 million in losses. Loss per share was -$0.07.
| Revenue | 65.38M |
| Gross Profit | 17.84M |
| Operating Income | -69.58M |
| Pretax Income | -93.81M |
| Net Income | -94.37M |
| EBITDA | -63.09M |
| EBIT | -69.58M |
| Loss Per Share | -$0.07 |
Full Income StatementBalance Sheet
The company has $129.98 million in cash and $135.14 million in debt, with a net cash position of -$5.17 million or -$0.00 per share.
| Cash & Cash Equivalents | 129.98M |
| Total Debt | 135.14M |
| Net Cash | -5.17M |
| Net Cash Per Share | -$0.00 |
| Equity (Book Value) | 574.68M |
| Book Value Per Share | 0.45 |
| Working Capital | 74.41M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$59.64 million and capital expenditures -$996,000, giving a free cash flow of -$60.64 million.
| Operating Cash Flow | -59.64M |
| Capital Expenditures | -996,000 |
| Free Cash Flow | -60.64M |
| FCF Per Share | -$0.05 |
Full Cash Flow StatementMargins
Gross margin is 27.29%, with operating and profit margins of -106.41% and -144.33%.
| Gross Margin | 27.29% |
| Operating Margin | -106.41% |
| Pretax Margin | -143.47% |
| Profit Margin | -144.33% |
| EBITDA Margin | -96.49% |
| EBIT Margin | -106.41% |
| FCF Margin | n/a |
